Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDL-AP7
Description: Selective NMDA antagonist
Chemical Name: DL-2-Amino-7-phosphonoheptanoic acid
Biological Activity for DL-AP7
DL-AP7 is a first generation phosphono NMDA antagonist. Anticonvulsant.
Technical Data for DL-AP7
| M. Wt | 225.18 |
| Formula | C7H16NO5P |
| Storage | Store at RT |
| CAS Number | 85797-13-3 |
| PubChem ID | 3122 |
| InChI Key | MYDMWESTDPJANS-UHFFFAOYSA-N |
| Smiles | NC(C(O)=O)CCCCCP(O)(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for DL-AP7
References for DL-AP7
References are publications that support the biological activity of the product.
Evans et al (1982) The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65 PMID: 7042024
Meldrum and Chapman (1994) Competitive NMDA antagonists as drugs. In The NMDA Receptor (2nd edition). Eds. G. L. Col 457
View Related Products by Target
View Related Products by Product Action
Keywords: DL-AP7, DL-AP7 supplier, Selective, Specific, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlu, Ionotropic, 78966-69-5, 0104, Tocris Bioscience
2 Citations for DL-AP7
Citations are publications that use Tocris products. Selected citations for DL-AP7 include:
Gustafson et al (2007) Endogenous D-serine contributes to NMDA-receptor-mediated light-evoked responses in the vertebrate retina. J Neurophysiol 98 122 PMID: 17507508
Stevens et al (2010) Light-evoked NMDA receptor-mediated currents are reduced by blocking D-serine synthesis in the salamander retina. Neuroreport 21 239 PMID: 20101193
Reviews for DL-AP7
There are currently no reviews for this product. Be the first to review DL-AP7 and earn rewards!
Have you used DL-AP7?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.